Novartis
NVS
1,618 hedge funds and large institutions have $21.3B invested in Novartis in 2026 Q2 according to their latest regulatory filings, with 132 funds opening new positions, 527 increasing their positions, 574 reducing their positions, and 88 closing their positions.
50% more first-time investments, than exits
New positions opened: 132 | Existing positions closed: 88
1% more funds holding
Funds holding: 1,601 → 1,618 (+17)
0.16% less ownership
Funds ownership: 6.83% → 6.67% (-0.16%)
3% less capital invested
Capital invested by funds: $22B → $21.3B (-$768M)
8% less repeat investments, than reductions
Existing positions increased: 527 | Existing positions reduced: 574
41% less funds holding in top 10
Funds holding in top 10: 17 → 10 (-7)
50% less call options, than puts
Call options by funds: $433M | Put options by funds: $871M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fisher Asset Management
Camas,
Washington
|
+$246M |
| 2 |
Holocene Advisors
New York
|
+$156M |
| 3 |
Millennium Management
New York
|
+$114M |
| 4 |
JP Morgan Chase
New York
|
+$68.9M |
| 5 |
WCM Investment Management
Laguna Beach,
California
|
+$66.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Dodge & Cox
San Francisco,
California
|
-$931M |
| 2 |
Goldman Sachs
New York
|
-$532M |
| 3 |
State Street
Boston,
Massachusetts
|
-$200M |
| 4 |
Primecap Management
Pasadena,
California
|
-$146M |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$91.3M |
NVS Hedge Fund Activity: Q2 2026 in Review
1,618 of the 8,305 institutional investors tracked by Wall St. Rank reported a position in Novartis (NVS) for Q2 2026, worth a combined $21.3B — down 3.5% from $22B a quarter earlier.
Buyers outnumbered sellers: 132 funds opened new NVS positions and 88 closed out — a net gain of 44 holders — while 527 added to existing stakes and 574 trimmed.
The largest buyer was Fisher Asset Management, adding an estimated $246M. The largest seller was Dodge & Cox, cutting an estimated $931M.
- 1,618 institutional investors held Novartis (NVS) as of Q2 2026, up from 1,601 in Q1 2026.
- Funds reported $21.3B of Novartis stock for Q2 2026, down 3.5% quarter-over-quarter.
- 132 funds opened new Novartis positions in Q2 2026 and 88 closed out, a net change of +44 holders.
- The largest Novartis buyer in Q2 2026 was Fisher Asset Management, an estimated $246M added.
- The largest Novartis seller in Q2 2026 was Dodge & Cox, an estimated $931M sold.
Based on aggregated 13F filings for Q2 2026.